
Taro Okamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/236395/publications.pdf Version: 2024-02-01



Τλρο Οκλμοτο

#	Article	IF	CITATIONS
1	Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocrine Journal, 2010, 57, 383-394.	0.7	90
2	Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology International, 2013, 4, 160-172.	0.7	23
3	Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. Journal of Diabetes Investigation, 2013, 4, 595-604.	1.1	21
4	A randomized, placebo†and sitagliptinâ€controlled trial of the safety and efficacy of omarigliptin, a onceâ€weekly dipeptidyl peptidaseâ€4 inhibitor, in <scp>J</scp> apanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1602-1609.	2.2	19
5	Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in <scp>J</scp> apanese subjects with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 2015, 17, 1033-1041.	2.2	18
6	A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy, 2017, 8, 793-810.	1.2	5
7	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism, 2021, 23, 2099-2108.	2.2	5
8	A randomized, placeboâ€controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, Obesity and Metabolism, 2021, 23, 1242-1251.	2.2	4
9	A randomized, placeboâ€controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, Obesity and Metabolism, 2021, 23, 1342-1350.	2.2	2
10	Factors associated with the glucoseâ€lowering efficacy of sitagliptin in Japanese patients with typeÂ2 diabetes mellitus: Pooled analysis of Japanese clinical trials. Journal of Diabetes Investigation, 2020, 11, 640-646.	1.1	1